CN109010375A - A kind of collyrium - Google Patents
A kind of collyrium Download PDFInfo
- Publication number
- CN109010375A CN109010375A CN201811057304.6A CN201811057304A CN109010375A CN 109010375 A CN109010375 A CN 109010375A CN 201811057304 A CN201811057304 A CN 201811057304A CN 109010375 A CN109010375 A CN 109010375A
- Authority
- CN
- China
- Prior art keywords
- collyrium
- lutein
- menthol
- hyaluronic acid
- tea polyphenols
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 235000012680 lutein Nutrition 0.000 claims abstract description 42
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims abstract description 42
- 229960005375 lutein Drugs 0.000 claims abstract description 42
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims abstract description 42
- 239000001656 lutein Substances 0.000 claims abstract description 42
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims abstract description 42
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims abstract description 42
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 38
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 38
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 36
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 36
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 36
- 239000000843 powder Substances 0.000 claims abstract description 35
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 34
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 34
- 229940041616 menthol Drugs 0.000 claims abstract description 34
- 241001122767 Theaceae Species 0.000 claims abstract description 33
- 239000008213 purified water Substances 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 241000196324 Embryophyta Species 0.000 claims abstract description 8
- 239000004599 antimicrobial Substances 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims description 34
- 238000003756 stirring Methods 0.000 claims description 20
- 238000010438 heat treatment Methods 0.000 claims description 14
- 238000004321 preservation Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 7
- 238000012856 packing Methods 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 6
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 5
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- 238000005342 ion exchange Methods 0.000 claims description 5
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 5
- 229960002646 scopolamine Drugs 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 4
- 238000005260 corrosion Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 210000001508 eye Anatomy 0.000 abstract description 53
- 230000000694 effects Effects 0.000 abstract description 13
- 230000004438 eyesight Effects 0.000 abstract description 13
- 208000003464 asthenopia Diseases 0.000 abstract description 9
- 208000001491 myopia Diseases 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 9
- 230000004379 myopia Effects 0.000 abstract description 8
- 239000003814 drug Substances 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract 2
- 239000003755 preservative agent Substances 0.000 description 7
- 230000002335 preservative effect Effects 0.000 description 7
- 230000004224 protection Effects 0.000 description 5
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 208000020564 Eye injury Diseases 0.000 description 3
- 206010038848 Retinal detachment Diseases 0.000 description 3
- 102000004330 Rhodopsin Human genes 0.000 description 3
- 108090000820 Rhodopsin Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003471 anti-radiation Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000001934 delay Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000004423 myopia development Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000003711 photoprotective effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010011844 Dacryocystitis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 201000008197 Laryngitis Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003820 Lipoxygenases Human genes 0.000 description 1
- 108090000128 Lipoxygenases Proteins 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 238000007539 photo-oxidation reaction Methods 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000009461 vacuum packaging Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/618—Molluscs, e.g. fresh-water molluscs, oysters, clams, squids, octopus, cuttlefish, snails or slugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
Abstract
The invention discloses a kind of collyrium formulas and preparation method thereof, belong to field of medicaments, the formula is grouped as by the group of following parts by weight: hyaluronic acid 0.01-0.1%, tea polyphenols 0.01-0.09%, lutein 0.01-0.09%, pearl powder 0.01-0.09%, menthol 0.01-0.1%, if it is 0.02-0.05% that non-real empty package, which need to add chemistry or plant antiseptic agent ratio, remaining proportion is purified water.Collyrium performance prepared by the present invention is mild, moist, can effectively clean, moisten eyes, alleviates the asthenopias symptoms such as dry and astringent, the sour swollen, sufferings of eyes, and quick light eyes have effect to alleviation asthenopia symptom needed for prevention and control myopia and prevention eye illness；The formula has both trophism, can protect eyesight.
Description
Technical field
The present invention relates to field of medicaments, specially a kind of collyrium.
Background technique
It is well known that " mesh labor is in view ", " falling sick from overwork ", once it is often to treat rather intractable chronic disease at disease.It is existing
Generation society, work, rhythm of life are increasingly accelerated, and people are increasingly longer in face of the time of the electrical screens such as mobile phone, computer, TV, by
In the reasons such as its screen display technology and radiation, if things go on like this not only can if not taking appropriate action to protection eyes
Cause eye-blurred, ocular are congested, eyes it is puckery itch, the symptoms such as acid is swollen, swelling and pain, also result in the more tears of eyes, cataract or glaucoma outer screen, conjunctiva
The serious consequences such as inflammation, keratitis, dacryocystitis, ulcer of the cornea, confused blind, near-sighted or even blindness.
China's sight protectio status causes anxiety, and pupil's rate of myopia is more than 20%, and junior school student's rate of myopia is more than 35%, high school student
Rate of myopia is more than 50%, and university student's rate of myopia is up to 70%, and middle-aged and the old's blurring of vision disease incidence is up to 80% or more.It is so high
Eyesight disease incidence, not country thinks little of --- country's constantly investment is tried to protect the eyesight of people, but so far can only be to give
Numerous patient-worn's glasses are main solution, and are worn glasses, and bring inconvenience to patient.In order to solve inconvenience,
Patient just attempts using multiple therapy methods and drug, it is desirable to be able to cure eye fatigue syndrome caused by view long --- as regarded
Power is fuzzy, conjunctival congestion, eye it is puckery itch, the symptoms such as acid is swollen, swelling and pain.Although patient uses miscellaneous remedy measures,
It is " palliative ", such as the under cover side effects such as toxic reaction, drug resistance, drug resistance of antibiotics eye drip drug；
And the physical therapy modalities of various eye illnesses --- including modes such as acupuncture, massage, eye exercises, therapeutic equipments, not only curative effect is also easy slowly
Recurrence.Eye can effectively be cleaned, the collyrium of improvement ocular environment has obvious effect, but current collyrium to sight protectio
Have a single function, be not able to satisfy the demand of people, in consideration of it, we provide it is a kind of have both cleaning, moisten, trophism washes eye
Liquid.
Summary of the invention
The purpose of the present invention is to provide a kind of collyriums, to solve the function of collyrium mentioned above in the background art
Single problem.
To achieve the above object, the invention provides the following technical scheme:
A kind of collyrium is grouped as by the group of following parts by weight: hyaluronic acid 0.01-0.01%, tea polyphenols 0.01-
0.09%, lutein 0.01-0.09%, pearl powder (hydrolyzate) 0.01-0.09%, menthol 0.01-0.1%, remaining ratio
Example is using the purified water through hyoscine made from the way of distillation, ion-exchange or hyperfiltration.
It as preferably 1, is grouped as by the group of following parts by weight: hyaluronic acid 0.01%, tea polyphenols 0.015%, lutein
0.02%, pearl powder (hydrolyzate) 0.02%, menthol 0.02%, remaining ratio are purified water.
It as preferably 2, is grouped as by the group of following parts by weight: hyaluronic acid 0.015%, tea polyphenols 0.02%, lutein
0.05%, pearl powder (hydrolyzate) 0.025%, menthol 0.02%, remaining ratio are all purified waters.
It as preferably 3, is grouped as by the group of following parts by weight: hyaluronic acid 0.02%, tea polyphenols 0.02%, lutein
0.03%, pearl powder (hydrolyzate) 0.02%, menthol 0.02%, remaining ratio are all purified waters.
Preferably, the preparation process of the collyrium includes the following steps:
S1: it gets out the hyaluronic acid of each component, tea polyphenols, lutein, pearl powder, menthol and suitable in advance
Water；
S2: ready hyaluronic acid, tea polyphenols and pearl powder are added in mixing vessel, and suitable purifying is added
Water is stirred evenly and is boiled；
S3: ready lutein is added into mixing vessel, and suitable distilled water is added during stirring to be made
Lutein dissolution, stirs evenly；
S4: ready menthol is added into mixing vessel, and agitating and heating is simultaneously kept the temperature；
S5: into mixing vessel plus purified water is to specified amount, and mixing filters to get colourless or yellowish clear liquid,
As collyrium.
S6: packing the collyrium prepared, if non-real empty package need to add chemistry or plant antiseptic agent, and
Preservative ratio is 0.02-0.05%.
Preferably, stirred evenly in step S2 boil during mixed every 60 minutes primary, keep the temperature 3 hours.
Preferably, the maximum temperature of the heating of step S4 is 100 DEG C, the time of heat preservation is 30 minutes.
The various effects for preparing raw material are as follows in collyrium provided by the present invention:
Hyaluronic acid also known as sodium hyaluronate are a kind of acid mucopolysaccharides, and hyaluronic acid is the tender important foundation substance of skin water,
It is also a kind of ingredient of human body, it has special water retention, and it is to send out at present that deal, which is more up to 100 times of itself weight,
The best substance of moisture retention in existing nature, referred to as ideal natural moisturizing factor.Hyaluronic acid is moistened with moisturizing, can
To lubricate eyes, the senses of discomfort such as the dry and astringent, foreign matter of eyes are eliminated, alleviate asthenopia, so that eyes are more bright.
Tea polyphenols have the function of removing free radical, can inhibit lipoxygenase and lipid peroxy in skin mitochondria and be turned into
With to have anti-aging effect；Tea polyphenols have excellent radiation-resisting functional, can absorb radioactive substance, prevent it in people
Diffusion in vivo；Tea polyphenols can effectively eliminate excessively with eye, electrical screen bring eye injuries, have the anti-radiation anti-aging of anti-blue light
Oxidation resistant effect；Simultaneously tea polyphenols have effects that the various pathogen of killing, germs and viruses, can eliminate and enter on eyeball
The pathogen such as bacterium, in conclusion tea polyphenols can protect eyesight.
Lutein be orange-yellow powder, pulpous state or liquid, it is not soluble in water, the organic solvents such as hexane are dissolved in, to photooxidation, light
Destroying has protective effect, is the primary pigments for constituting human eye retina's macular region；Lutein can protect eyes not light
Line loss evil, delays the aging of eyes and prevents lesion；It is thin to can promote retina as antioxidant and photoprotection for lutein
The regeneration of visual purple in born of the same parents, capable of preventing myopia, myopia development and detached retina, and eyesight, protection eyesight can be promoted.
Eye illness, Ke Yiming can be controlled containing 18 kinds of amino acid, external applications such as leucine, methionine, alanine after pearl powder hydrolysis
Mesh, can improve that eye is swollen, eye is itched, ophthalmodynia, eye are dry, eye is puckery symptoms, the long-time service such as cannot persistently read and can protect eyesight.
Menthol is a kind of organic compound, and colorless needle crystals or granular act on skin or mucous membrane, is had refrigerant antipruritic
Effect, it is for oral administration to can be used for headache and nose, pharynx, laryngitis, it can be used as freshener and ophthalmic preparations be added, to mitigate Ocular irritation,
Alleviate that eye is dry and astringent, burning heat sensation.
Compared with prior art, the beneficial effects of the present invention are:
1, this collyrium has good sterile biological activity, and minimum to eye irritation effect, can not destroy eyes
Under the premise of the lipid layer of tear, aqueous layer, mucin layer, alleviates the asthenopias symptoms such as dry and astringent, the sour swollen, sufferings of eyes, alleviate
Eye strain.
2, the hyaluronic acid in this collyrium has moisturizing, moisten effect, can lubricate eyes, and it is dry and astringent, different to eliminate eyes
The senses of discomfort such as object alleviate asthenopia；Tea polyphenols can effectively eliminate excessively with eye, electrical screen bring eye injuries, have anti-
Blue light, anti-radiation, anti-aging, oxidation resistant effect；Lutein can protect eyes not by phototoxis, delay the aging of eyes
And lesion is prevented, it can promote the regeneration of visual purple in retina cell as antioxidant and photoprotection agent, can prevent
Myopia, myopia development and detached retina, and eyesight, protection eyesight can be promoted；Pearl powder can improve eye is swollen, eye is itched, ophthalmodynia,
Eye is dry, eye is puckery symptoms, the long-time service such as cannot persistently read and can protect eyesight；Menthol can be used as freshener and eye system be added
Agent, can alleviate that eye is dry and astringent, burning heat sensation.
3, present invention cooperation vacuum packaging can be free of preservative, can be used for a long time.
Specific embodiment
Below in conjunction with the embodiment of the present invention, technical scheme in the embodiment of the invention is clearly and completely described,
Obviously, described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Based in the present invention
Embodiment, every other embodiment obtained by those of ordinary skill in the art without making creative efforts, all
Belong to the scope of protection of the invention.
Embodiment 1
A kind of collyrium is grouped as by the group of following parts by weight: hyaluronic acid 0.01-0.1%, tea polyphenols 0.01-
0.09%, lutein 0.01-0.09%, pearl powder (hydrolyzate) 0.01-0.09%, menthol 0.01-0.1%, remaining ratio
Example is using the purified water through hyoscine made from the way of distillation, ion-exchange or hyperfiltration.
Preferably as one kind of the invention, the group by following parts by weight in the present embodiment is grouped as: hyaluronic acid
0.01%, tea polyphenols 0.015%, lutein 0.02%, pearl powder (hydrolyzate) 0.02%, menthol 0.02%, remaining ratio
Example is purified water.
The preparation process of the collyrium includes the following steps:
S1: it gets out the hyaluronic acid of each component, tea polyphenols, lutein, pearl powder, menthol and suitable in advance
Water；
S2: ready hyaluronic acid, tea polyphenols and pearl powder are added in mixing vessel, and suitable purifying is added
Water is stirred evenly and is boiled；
S3: ready lutein is added into mixing vessel, and suitable distilled water is added during stirring to be made
Lutein dissolution, stirs evenly；
S4: ready menthol is added into mixing vessel, and agitating and heating is simultaneously kept the temperature；
S5: into mixing vessel plus purified water is to specified amount, and mixing filters to get colourless or yellowish clear liquid,
As collyrium.
S6: packing the collyrium prepared, if non-real empty package need to add chemistry or plant antiseptic agent, and
Preservative ratio is 0.02-0.05%.
Preferably as one kind of the invention, it stirs evenly in step S2 and was mixed once during boiling every 60 minutes, heat preservation 3 is small
When.
Preferably as one kind of the invention, the maximum temperature of the heating of step S4 is 100 DEG C, and the time of heat preservation is 30 points
Clock.
Embodiment 2
A kind of collyrium is grouped as by the group of following parts by weight: hyaluronic acid 0.01-0.1%, tea polyphenols 0.01-
0.09%, lutein 0.01-0.09%, pearl powder (hydrolyzate) 0.01-0.09%, menthol 0.01-0.1%, remaining ratio
Example is using the purified water through hyoscine made from the way of distillation, ion-exchange or hyperfiltration.
Preferably as one kind of the invention, the group by following parts by weight in the present embodiment is grouped as: hyaluronic acid
0.015%, tea polyphenols 0.02%, lutein 0.05%, pearl powder (hydrolyzate) 0.025%, menthol 0.02%, remaining ratio
Example is all purified water.
The preparation process of the collyrium includes the following steps:
S1: it gets out the hyaluronic acid of each component, tea polyphenols, lutein, pearl powder, menthol and suitable in advance
Water；
S2: ready hyaluronic acid, tea polyphenols and pearl powder are added in mixing vessel, and suitable purifying is added
Water is stirred evenly and is boiled；
S3: ready lutein is added into mixing vessel, and suitable distilled water is added during stirring to be made
Lutein dissolution, stirs evenly；
S4: ready menthol is added into mixing vessel, and agitating and heating is simultaneously kept the temperature；
S5: into mixing vessel plus purified water is to specified amount, and mixing filters to get colourless or yellowish clear liquid,
As collyrium.
S6: packing the collyrium prepared, if non-real empty package need to add chemistry or plant antiseptic agent, and
Preservative ratio is 0.02-0.05%.
Preferably as one kind of the invention, it stirs evenly in step S2 and was mixed once during boiling every 60 minutes, heat preservation 3 is small
When.
Preferably as one kind of the invention, the maximum temperature of the heating of step S4 is 100 DEG C, and the time of heat preservation is 30 points
Clock.
Embodiment 3
A kind of collyrium is grouped as by the group of following parts by weight: hyaluronic acid 0.01-0.1%, tea polyphenols 0.01-
0.09%, lutein 0.01-0.09%, pearl powder (hydrolyzate) 0.01-0.09%, menthol 0.01-0.1%, remaining ratio
Example is using the purified water through hyoscine made from the way of distillation, ion-exchange or hyperfiltration.
Preferably as one kind of the invention, the group by following parts by weight in the present embodiment is grouped as: hyaluronic acid
0.02%, tea polyphenols 0.02%, lutein 0.03%, pearl powder (hydrolyzate) 0.02%, menthol 0.02%, remaining ratio
It is all purified water.
The preparation process of collyrium includes the following steps:
S1: it gets out the hyaluronic acid of each component, tea polyphenols, lutein, pearl powder, menthol and suitable in advance
Water；
S2: ready hyaluronic acid, tea polyphenols and pearl powder are added in mixing vessel, and suitable purifying is added
Water is stirred evenly and is boiled；
S3: ready lutein is added into mixing vessel, and suitable distilled water is added during stirring to be made
Lutein dissolution, stirs evenly；
S4: ready menthol is added into mixing vessel, and agitating and heating is simultaneously kept the temperature；
S5: into mixing vessel plus purified water is to specified amount, and mixing filters to get colourless or yellowish clear liquid,
As collyrium.
S6: packing the collyrium prepared, if non-real empty package need to add chemistry or plant antiseptic agent, and
Preservative ratio is 0.02-0.05%.
Preferably as one kind of the invention, it stirs evenly in step S2 and was mixed once during boiling every 60 minutes, heat preservation 3 is small
When.
Preferably as one kind of the invention, the maximum temperature of the heating of step S4 is 100 DEG C, and the time of heat preservation is 30 points
Clock.
Comparative example 1
A kind of collyrium is grouped as by the group of following parts by weight: hyaluronic acid 0.05%, tea polyphenols 0.05%, lutein
0.05%, pearl powder (hydrolyzate) 0.05%, menthol 0.05%, remaining ratio are all purified waters.
The preparation process of collyrium includes the following steps:
S1: it gets out the hyaluronic acid of each component, tea polyphenols, lutein, pearl powder, menthol and suitable in advance
Water；
S2: ready hyaluronic acid, tea polyphenols and pearl powder are added in mixing vessel, and suitable purifying is added
Water is stirred evenly and is boiled；
S3: ready lutein is added into mixing vessel, and suitable distilled water is added during stirring to be made
Lutein dissolution, stirs evenly；
S4: ready menthol is added into mixing vessel, and agitating and heating is simultaneously kept the temperature；
S5: into mixing vessel plus purified water is to specified amount, and mixing filters to get colourless or yellowish clear liquid,
As collyrium.
S6: packing the collyrium prepared, if non-real empty package need to add chemistry or plant antiseptic agent, and
Preservative ratio is 0.02-0.05%.
Preferably as one kind of the invention, it stirs evenly in step S2 and was mixed once during boiling every 60 minutes, heat preservation 3 is small
When.
Preferably as one kind of the invention, the maximum temperature of the heating of step S4 is 100 DEG C, and the time of heat preservation is 30 points
Clock.
Comparative example 2
A kind of collyrium is grouped as by the group of following parts by weight: hyaluronic acid 0.1%, tea polyphenols 0.1%, lutein
0.1%, pearl powder (hydrolyzate) 0.1%, menthol 0.1%, remaining ratio are all purified waters.
The preparation process of collyrium includes the following steps:
S1: it gets out the hyaluronic acid of each component, tea polyphenols, lutein, pearl powder, menthol and suitable in advance
Water；
S2: ready hyaluronic acid, tea polyphenols and pearl powder are added in mixing vessel, and suitable purifying is added
Water is stirred evenly and is boiled；
S3: ready lutein is added into mixing vessel, and suitable distilled water is added during stirring to be made
Lutein dissolution, stirs evenly；
S4: ready menthol is added into mixing vessel, and agitating and heating is simultaneously kept the temperature；
S5: into mixing vessel plus purified water is to specified amount, and mixing filters to get colourless or yellowish clear liquid,
As collyrium.
S6: packing the collyrium prepared, if non-real empty package need to add chemistry or plant antiseptic agent, and
Preservative ratio is 0.02-0.05%.
Preferably as one kind of the invention, it stirs evenly in step S2 and was mixed once during boiling every 60 minutes, heat preservation 3 is small
When.
Preferably as one kind of the invention, the maximum temperature of the heating of step S4 is 100 DEG C, and the time of heat preservation is 30 points
Clock.
By the collyrium that above three groups of embodiments obtain and collyrium and traditional collyrium that two comparative examples obtain
Experiment is compared, after a period of use, the correlation data obtained is as follows:
Compared by above-mentioned experimental data it can be concluded that, through it is provided by the invention formula and technique made from collyrium in items
Traditional collyrium is significantly better than that in index.
Collyrium of the invention has cleaning eyes when in use, by eye syringe, after cleaning, keeps 30 seconds left sides of posture
The right side.Collyrium of the invention has good sterile biological activity, and minimum to eye irritation effect, can not destroy eye
Under the premise of the lipid layer of eyeball tear, aqueous layer, mucin layer, alleviate the asthenopias symptoms such as dry and astringent, the sour swollen, sufferings of eyes.This
Hyaluronic acid in collyrium has moisturizing, moisten effect, can lubricate eyes, eliminates the senses of discomfort such as the dry and astringent, foreign matter of eyes, delays
Solve asthenopia；Tea polyphenols can effectively eliminate excessively with eye, electrical screen bring eye injuries, have anti-blue light, anti-radiation, anti-
Aging, oxidation resistant effect；Lutein can protect eyes not by phototoxis, delays the aging of eyes and prevents lesion, make
It can promote the regeneration of visual purple in retina cell, capable of preventing myopia, myopia development for antioxidant and photoprotection agent
And detached retina, and eyesight, protection eyesight can be promoted；Pearl powder can improve that eye is swollen, eye is itched, ophthalmodynia, eye are dry, eye is puckery cannot
The persistently symptoms such as reading, long-time service can protect eyesight；Menthol can be used as freshener and ophthalmic preparations be added, and can alleviate eye
Portion is dry and astringent, burning heat sensation.
The basic principles, main features and advantages of the present invention have been shown and described above.The technology of the industry
For personnel it should be appreciated that the present invention is not limited to the above embodiments, described in the above embodiment and specification is only the present invention
Preference, be not intended to limit the invention, without departing from the spirit and scope of the present invention, the present invention also has various
Changes and improvements, these changes and improvements all fall within the protetion scope of the claimed invention.The claimed scope of the invention is by institute
Attached claims and its equivalent thereof.
Claims (7)
1. it is a kind of with cleaning, moist, trophism collyrium, it is grouped as by the group of following parts by weight: hyaluronic acid 0.01-
0.1%, tea polyphenols 0.01-0.09%, lutein 0.01-0.09%, pearl powder (hydrolyzate) 0.01-0.09%, menthol 0.01-
0.1%, remaining ratio is using the purified water through hyoscine made from the way of distillation, ion-exchange or hyperfiltration.
2. collyrium according to claim 1, it is characterised in that be grouped as by the group of following parts by weight: hyaluronic acid
0.01%, tea polyphenols 0.015%, lutein 0.02%, pearl powder (hydrolyzate) 0.02%, menthol 0.02%, remaining ratio are pure
Change water.
3. collyrium according to claim 1, it is characterised in that be grouped as by the group of following parts by weight: hyaluronic acid
0.015%, tea polyphenols 0.02%, lutein 0.05%, pearl powder (hydrolyzate) 0.025%, menthol 0.02%, remaining ratio is all
It is purified water.
4. collyrium according to claim 1, it is characterised in that be grouped as by the group of following parts by weight: hyaluronic acid
0.02%, tea polyphenols 0.02%, lutein 0.03%, pearl powder (hydrolyzate) 0.02%, menthol 0.02%, remaining ratio are all
Purified water.
5. collyrium according to any one of claims 1-4, it is characterised in that the preparation process of the collyrium includes
Following steps:
S1: it gets out hyaluronic acid, tea polyphenols, lutein, pearl powder, menthol and the suitable water of each component in advance；
S2: ready hyaluronic acid, tea polyphenols and pearl powder being added in mixing vessel, and suitable purified water is added,
It stirs evenly and boils；
S3: ready lutein is added into mixing vessel, and suitable distilled water is added during stirring keeps leaf yellow
Element dissolution, stirs evenly；
S4: ready menthol is added into mixing vessel, and agitating and heating is simultaneously kept the temperature；
S5: into mixing vessel plus purified water is to specified amount, mixes, filters to get colourless or yellowish clear liquid, as
Collyrium；
S6: packing the collyrium prepared, if non-real empty package need to add chemistry or plant antiseptic agent, and anti-corrosion
Agent ratio is 0.02-0.05%.
6. collyrium according to claim 5, it is characterised in that: stirred evenly in step S2 during boiling every 60 minutes
Mix primary, heat preservation 3 hours.
7. the preparation method of collyrium according to claim 5, it is characterised in that: the maximum temperature of the heating of step S4 is
100 DEG C, the time of heat preservation is 30 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811057304.6A CN109010375B (en) | 2018-09-11 | 2018-09-11 | Eye lotion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811057304.6A CN109010375B (en) | 2018-09-11 | 2018-09-11 | Eye lotion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN109010375A true CN109010375A (en) | 2018-12-18 |
| CN109010375B CN109010375B (en) | 2022-04-15 |
Family
ID=64620947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811057304.6A Active CN109010375B (en) | 2018-09-11 | 2018-09-11 | Eye lotion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109010375B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110787211A (en) * | 2019-10-30 | 2020-02-14 | 通化力神保健品有限公司 | Ginseng eye lotion and preparation method thereof |
| CN112842936A (en) * | 2021-03-15 | 2021-05-28 | 傅博 | Eye cleaning solution and preparation method thereof |
| CN113925828A (en) * | 2021-09-23 | 2022-01-14 | 重庆视健眼健康产业有限公司 | Borneol eye lotion |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1628759A (en) * | 2004-10-13 | 2005-06-22 | 凌沛学 | Chinese medicinal formulation for treating asthenopia syndrome and its preparation method |
| WO2010101555A1 (en) * | 2009-03-06 | 2010-09-10 | Johnson & Johnson Vision Care, Inc. | A process for forming stabilized ophthalmic solutions |
| EP2494953A1 (en) * | 2009-10-26 | 2012-09-05 | Nissan Chemical Industries, Ltd. | Cosmetic and external skin preparation, and medical instrument |
| CN103417733A (en) * | 2013-09-10 | 2013-12-04 | 南方医科大学 | Medicine composition for relieving eyestrain |
| CN104436156A (en) * | 2013-09-25 | 2015-03-25 | 青岛中人智业生物科技有限公司 | Eyesight protective agent xanthophyll eye preparation and preparation process thereof |
| JP2015197479A (en) * | 2014-03-31 | 2015-11-09 | 株式会社メニコン | Ophthalmic composition liquid and method of using the same |
| CN105878573A (en) * | 2016-05-20 | 2016-08-24 | 王义明 | Composition for relieving visual fatigue |
| CN106620639A (en) * | 2017-01-23 | 2017-05-10 | 湖北丽生堂生物科技有限公司 | Lutein-containing compound plant eye mask with effect of supplementing eye nutrients to resist wrinkles |
| JP2018028673A (en) * | 2017-10-03 | 2018-02-22 | 株式会社メニコン | Ophthalmic composition liquid and method of using the same |
| CN107802561A (en) * | 2017-12-15 | 2018-03-16 | 廖勇辉 | One kind nursing eye gel and its production method |
-
2018
- 2018-09-11 CN CN201811057304.6A patent/CN109010375B/en active Active
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1628759A (en) * | 2004-10-13 | 2005-06-22 | 凌沛学 | Chinese medicinal formulation for treating asthenopia syndrome and its preparation method |
| WO2010101555A1 (en) * | 2009-03-06 | 2010-09-10 | Johnson & Johnson Vision Care, Inc. | A process for forming stabilized ophthalmic solutions |
| EP2494953A1 (en) * | 2009-10-26 | 2012-09-05 | Nissan Chemical Industries, Ltd. | Cosmetic and external skin preparation, and medical instrument |
| CN103417733A (en) * | 2013-09-10 | 2013-12-04 | 南方医科大学 | Medicine composition for relieving eyestrain |
| CN104436156A (en) * | 2013-09-25 | 2015-03-25 | 青岛中人智业生物科技有限公司 | Eyesight protective agent xanthophyll eye preparation and preparation process thereof |
| JP2015197479A (en) * | 2014-03-31 | 2015-11-09 | 株式会社メニコン | Ophthalmic composition liquid and method of using the same |
| CN105878573A (en) * | 2016-05-20 | 2016-08-24 | 王义明 | Composition for relieving visual fatigue |
| CN106620639A (en) * | 2017-01-23 | 2017-05-10 | 湖北丽生堂生物科技有限公司 | Lutein-containing compound plant eye mask with effect of supplementing eye nutrients to resist wrinkles |
| JP2018028673A (en) * | 2017-10-03 | 2018-02-22 | 株式会社メニコン | Ophthalmic composition liquid and method of using the same |
| CN107802561A (en) * | 2017-12-15 | 2018-03-16 | 廖勇辉 | One kind nursing eye gel and its production method |
Non-Patent Citations (6)
| Title |
|---|
| SONG LN等: "Preparation and properties of thermosensitive in situ gel for ophthalmic formulation containing pearl hydrolyzate", 《YAO XUE XUE BAO》 * |
| SOUSA-MARTINS D等: "Comparing the mode of action of intraocular lutein-based dyes with synthetic dyes", 《COMPARATIVE STUDY》 * |
| 刘晓萃等: "眼球老化的研究进展 ", 《眼科新进展》 * |
| 张良晓: "高效液相色谱在药物分析中的应用研究进展 ", 《内蒙古石油化工》 * |
| 昭阳: "缓解眼疲劳的营养素知多少 ", 《江苏卫生保健》 * |
| 罗毅等: "七叶洋地黄双苷滴眼液对老年黄斑变性的疗效观察和机制初探 ", 《中国生化药物杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110787211A (en) * | 2019-10-30 | 2020-02-14 | 通化力神保健品有限公司 | Ginseng eye lotion and preparation method thereof |
| CN112842936A (en) * | 2021-03-15 | 2021-05-28 | 傅博 | Eye cleaning solution and preparation method thereof |
| CN113925828A (en) * | 2021-09-23 | 2022-01-14 | 重庆视健眼健康产业有限公司 | Borneol eye lotion |
Also Published As
| Publication number | Publication date |
|---|---|
| CN109010375B (en) | 2022-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109010375A (en) | A kind of collyrium | |
| CN101322743A (en) | Formulation capable of repairing lesion and damnification of eye and improving asthenopia and preparation thereof | |
| CN102178925A (en) | Novel eyesight protective agent lutein ophthalmic preparation | |
| CN103961556A (en) | Dendrobium officinale oculentum for relieving asthenopia | |
| CN109010761A (en) | A kind of eye externally applied drug and preparation method thereof alleviated visual fatigue and improve eyesight | |
| CN102166203B (en) | Eye pad for alleviating eye fatigue and preparation method thereof | |
| CN108904633A (en) | A kind of eye ointment and preparation method thereof improving eyesight | |
| CN108186733A (en) | A kind of pharmaceutical gel patch and its preparation method and application | |
| CN104474009A (en) | Eye cleaning liquid and preparation method thereof | |
| CN109908198A (en) | A kind of corn flower collyrium | |
| CN106620639A (en) | Lutein-containing compound plant eye mask with effect of supplementing eye nutrients to resist wrinkles | |
| CN101284048A (en) | Formulations for effectively improving hypometropia, asthenopia, cataract, eyeground pathological changes | |
| CN1285349C (en) | Chinese medicinal formulation for treating asthenopia syndrome and its preparation method | |
| CN113925828A (en) | Borneol eye lotion | |
| CN104436156A (en) | Eyesight protective agent xanthophyll eye preparation and preparation process thereof | |
| CN105902686A (en) | In-situ gel eyewash containing nano-carbon crystals and preparation method thereof | |
| CN109453151B (en) | Pharmaceutical composition for eyes, preparation method and application thereof | |
| CN106109499A (en) | A kind of Apostichopus enzymolysis liquid collyrium and preparation method | |
| CN111568869A (en) | Freeze-dried powder preparation for preventing and improving and nursing xerophthalmia and preparation method thereof | |
| CN111110817A (en) | Traditional Chinese medicine composition for treating eye diseases, preparation method and application thereof | |
| CN105168237A (en) | Compound gel moisturizing eye drops | |
| CN114099551B (en) | Asthenopia-relieving and eye-moistening composition | |
| CN110302357A (en) | A kind of external application eyesight-improving health care function Chinese medicine composition and preparation method thereof | |
| CN109820890A (en) | A kind of pharmaceutical composition and its preparation method and application with alleviation visual fatigue effect | |
| CN109222086A (en) | A kind of composition and its application and health food with efficacy of relieving visual fatigue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20231214 Address after: Room 1008, No. 289-7 Wengjiao Road, Haicang District, Xiamen City, Fujian Province, 361000 Patentee after: Xiamen Renmiao Dekang Medical Technology Co.,Ltd. Address before: 361026 No. 108 Haifu Road, Haicang District, Xiamen City, Fujian Province Patentee before: XIAMEN AOUKE HEALTH TECHNOLOGY Co.,Ltd. |